BioReperia AB

BioReperia AB is a privately owned Swedish biotechnology company based in Linköping that was founded in September 2015 on technology developed at Linköping University. The company focuses on oncology, providing in-vivo zebrafish-based tumor xenograft (ZTX®) services that aim to accelerate anti-cancer drug discovery and support personalized cancer treatment decisions. Its name derives from the Latin word 'reperio', meaning discovery or research, a term used by ancient Roman scientists to describe their work identifying new ways of treating diseases. BioReperia's core offering is the ZTX® platform, which is used in two main service lines. The ZTX® PREDICT platform is a CE-certified precision medicine solution that identifies the most effective anti-cancer drug for individual patients within five days, providing clinical decision support for pharmaceutical or surgical treatment. The ZTX® ONCOLEADS platform is a humanized, in-vivo oncology drug discovery service that mimics the complex tumor environment, allowing pharmaceutical and academic customers to select the best lead candidates for further development within five days. The company states that since 2015 its ZTX® ONCOLEADS platform has helped pharmaceutical companies accelerate drug discovery, particularly for immunotherapies and targeted therapies, reducing costs and enhancing clinical trial success. BioReperia serves clients worldwide, including biopharma companies, academic researchers, and healthcare professionals, and also engages directly with cancer patients and investors. It positions itself as a pioneer in metastatic risk assessment and states that ZTX® PREDICT sets a new standard in diagnostics. The company collaborates with partners such as Charles River Laboratories, InVivo Biosystems, and Inaphea Biolabs to expand access to tumor models and preclinical services. The ZTX® platform supports all PDX models from Charles River Laboratories' Tumor Compendium. As a privately owned company, BioReperia does not disclose a stock ticker or public listing. Its headquarters are in Linköping, Sweden, and it operates internationally, advancing oncology research and aiming to improve patient access to life-saving treatments.

BioReperia AB was founded in September 2015 in Linköping, Sweden, based on technology developed at Linköping University. The company was established as a privately owned entity focused on oncology, with the goal of providing unique services that accelerate anti-cancer drug discovery and help move new drug candidates more efficiently from preclinical to early-stage clinical development. The company's name, BioReperia, is derived from the Latin word 'reperio', meaning discovery or research. According to the company, this term was used by ancient Roman scientists to describe their work identifying new ways of treating diseases, reflecting BioReperia's focus on discovery and innovation in cancer treatment. Since its founding, BioReperia has developed and commercialized its ZTX® platform, a zebrafish tumor xenograft technology used for both drug discovery and precision medicine. The ZTX® ONCOLEADS platform has been available since 2015 and is used by pharmaceutical companies to accelerate drug discovery, particularly for immunotherapies and targeted therapies. The ZTX® PREDICT platform is a CE-certified precision medicine solution that provides accurate predictions of cancer drug efficacy within five days, aiding personalized treatment planning and improving patient outcomes. BioReperia describes itself as a pioneer in metastatic risk assessment, stating that ZTX® PREDICT sets a new standard in diagnostics. Over time, BioReperia has built a network of strategic partnerships to expand its reach and capabilities. Partners include Charles River Laboratories, whose oncology services and tumor models support preclinical testing; InVivo Biosystems, which provides in vivo modeling and genetic analysis; and Inaphea Biolabs, which offers drug discovery services including biomarker analysis and preclinical screening. The ZTX® platform supports all PDX models from Charles River Laboratories' Tumor Compendium, allowing customers to evaluate selected models or receive assistance from BioReperia. BioReperia serves clients worldwide, including biopharma companies, academic researchers, and healthcare professionals, and also engages with cancer patients and investors. The company remains privately owned and continues to advance oncology research with the aim of improving patient access to life-saving treatments.

• 2015

  BioReperia AB founded in September 2015 in Linköping, Sweden, based on technology developed at Linköping University.

• 2015

  ZTX® ONCOLEADS platform available since 2015, helping pharmaceutical companies accelerate drug discovery.

• ZTX® PREDICT platform receives CE certification as a precision medicine solution.

• Partnerships established with Charles River Laboratories, InVivo Biosystems, and Inaphea Biolabs.

Pioneer in metastatic risk assessment and provider of CE-certified zebrafish tumor xenograft platforms for precision medicine and oncology drug discovery.

• ZTX® PREDICT

  CE-certified precision medicine platform that identifies the most efficient anti-cancer drug for individual patients within 5 days, providing clinical decision support for pharmaceutical or surgical treatment.

• ZTX® ONCOLEADS

  Humanized, in-vivo oncology drug discovery platform that mimics the complex tumor environment, allowing selection of the best lead candidates for further pharmaceutical development within 5 days.

1. 1Changing the gameplan for cancer patients - Changing the gameplan for cancer patientsbioreperia.com
2. 2Company - BioReperiabioreperia.com
3. 3Partner services - BioReperiabioreperia.com
4. 4BioReperia AB (Sweden)wikidata.org